Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Private equity firms eye $7bn mobile office giant Willscot
Willscot Holdings, a $7bn leader in mobile office solutions, is reportedly attracting interest from private equity firms. While no formal sales process is underway, sources indicate that at least one buyout firm has engaged bankers to explore a potential acquisition....
Astorg acquires FUJIFILM Irvine Scientific’s medical media business to expand MedTech portfolio
FUJIFILM Irvine Scientific will sell its Medical Media Business Unit to Astorg, a leading European private equity firm. The deal, expected to close on April 1, 2025, will integrate the MBU into Astorg’s growing MedTech platform, which recently added Hamilton Thorne...
Bain Capital emerges as preferred bidder for Mitsubishi Chemical’s $3bn pharma business
Mitsubishi Chemical Group named Bain Capital as the preferred bidder for its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma. The potential transaction, valued at over $3bn, is part of Mitsubishi Chemical’s ongoing efforts to streamline its portfolio. While...